Summary
Conclusion
the dossier summarised in one paragraphThe file of DERMAK contains 2 historical bankruptcy publications, as published in the Belgian State Gazette. The computed 12-month bankruptcy probability is 1.3% (low). The 2024 annual accounts show equity of €56k and a net result of €131k. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 32% of 3354 sector peers (fiscal year 2024).
Based on the State Gazette, CBE and 7 annual accounts.
Bankruptcy probability (12 mo)
Checked model v1 · free for everyoneStatistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Insolvency timeline
2 eventsTrust signals
1 signalAdministrative Flags
Financials
Annual accounts & ratios
Source: NBB · 2024How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 7.3% | 25.2% | |
| Net result | €131k | €4k | |
| Equity | €56k | €23k | |
| Gross operating margin | €201k | €19k | |
| Staff costs | €41k | €27k |
| Fiscal year | 2024 |
|---|---|
| Revenue | €1.95M |
| EBITDA | €147k |
| Net profit | €131k |
| Cash flow | €146k |
| Staff costs | €41k |
| Income taxes | - |
| Dividends | - |
| Total assets | €765k |
| Equity | €56k |
| Debt | €709k |
| of which ≤ 1y | €709k |
| of which > 1y | - |
| Working capital | €41k |
| Employees (FTE) | - |
| 2024 | |
|---|---|
| Current ratio | 1.06 |
| Quick ratio | 0.74 |
| Working capital ratio | 5.3% |
| Solvency | 7.3% |
| Debt / equity | 12.72 |
| Long-term debt ratio | - |
| Interest coverage | 244.75 |
| Gross margin | 10.1% |
| Net margin | 6.7% |
| ROA | 17.2% |
| ROE | 235.8% |
| EBITDA margin | 7.5% |
| Days sales outstanding | 79d |
| Days payable outstanding | 140d |
| Inventory turnover | 7.72 |
| Days inventory (DSI) | 47d |
| Line item | Code | 2024 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €765k |
| Fixed assets | 21/28 | €15k |
| Tangible fixed assets | 22/27 | €11k |
| Financial fixed assets | 28 | €4k |
| Current assets | 29/58 | €750k |
| Stocks & contracts in progress | 3 | €227k |
| Amounts receivable within one year | 40/41 | €507k |
| Cash & bank | 54/58 | €15k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €765k |
| Equity | 10/15 | €56k |
| Contributions / capital | 10/11 | €19k |
| Accumulated profits (losses) | 14 | €37k |
| Amounts payable | 17/49 | €709k |
| Amounts payable within one year | 42/48 | €709k |
| Trade debts payable within one year | 44 | €673k |
| Income statement | ||
| Turnover | 70 | €1.95M |
| Gross operating margin | 9900 | €201k |
| Operating result | 9901 | €132k |
| Financial charges | 65 | €599 |
| Result before taxes | 9903 | €131k |
| Net result for the period | 9904 | €131k |
| Result to be appropriated | 9905 | €131k |
Health barometer
FY 2024 · computedUnlock the full score breakdown, per-year score history and the indicative credit limit with Plus.
See plans →Directors
Directors & mandates
No directors or mandates are on record for this company in the CBE. Not every legal form publishes directors; if they appear in the Belgian State Gazette later, they show up here automatically.
Insolvency mandates
1 mandate| Role | Name | Tenure | Source |
|---|---|---|---|
| Curator | JOAN DUBAERE KEIZER KARELLAAN 586 BUS 9,
1082 SINT-AGATHA-BERCHEM |
30-09-2025 → present | Belgian State Gazette |
Legal Structure
| NACE primary | Niet-gespecialiseerde groothandel in niet-diepgevroren voedingsmiddelen, dranken en genotmiddelen(46392) |
| Legal form | Private limited company(610) |
| Incorporation | 02-02-2017 |
| Status | Active |
| Postal code | 1080 |
| First BS signal | 10-10-2025 |
| Latest BS signal | 17-11-2025 |
Structure & network
Company structure: linked entities
1 linked entityLocations & real estate
Establishment units
1 locationReal-estate footprint
Source: CBE × cadastre · address linkingParcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 21523B0805/00B006 | Brussels | 4,580 m² | 1 · 5,650 m² | 12.1 m · 2 fl. |
Publications
Lifecycle & Insolvency Signals
2 events from the State GazetteTime machine: BS events + macro context
2021-2026Belgisch Staatsblad · acts
1 acts28-12-2023 Discharge granted to the board
Analysis
Snowflake analysis
financial profile on 5 axesStrong profile, led by stability.
Ask AI about this company
Checked AISoon: ask questions about this dossier, risks, curator, sector comparison, answered from the official data on this page.
AI due-diligence brief
Checked AIGenerate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
Credit advice
verdict per customer and amountSimilar
Similar companies
Same sector, ranked by comparable sizeCompany registry
Company registry (CBE)
Crossroads Bank| Legal nameFR | DERMAK |